Vigil Neuroscience, Inc. (VIGL)
After hours:
| Previous close | 3.2850 |
| Open | 3.3400 |
| Bid | 3.0800 x 100 |
| Ask | 3.2300 x 100 |
| Day's range | 3.0400 - 3.4100 |
| 52-week range | 2.5000 - 11.1100 |
| Volume | |
| Avg. volume | 93,957 |
| Market cap | 119.518M |
| Beta (5Y monthly) | 1.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.1300 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 16.75 |
GlobeNewswireVigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14th at 11:30 a.m. E.T. To register for the live event, please click here. The webcast will also be available on the Company’s website on the “E
- GuruFocus.com
Vigil Neuroscience Inc (VIGL) Q1 2024 Earnings: Challenges Persist Amid Clinical Developments
Financial and Operational Highlights with a Glimpse into Future Milestones
- GlobeNewswire
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
– Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer trial evaluating VG-3927 for Alzheimer’s disease ongoing; Interim data analysis on track for mid-2024 – WATERTOWN, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial re
